These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 19321593

  • 41. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
    Fejzo MS, Dering J, Ginther C, Anderson L, Ramos L, Walsh C, Karlan B, Slamon DJ.
    Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
    [Abstract] [Full Text] [Related]

  • 42. [Expressions of Cx43 and Skp2 in epithelial ovarian tumor and their clinical significances].
    Hu YQ, Liu YJ.
    Ai Zheng; 2005 Jan; 24(1):104-9. PubMed ID: 15642212
    [Abstract] [Full Text] [Related]

  • 43. [Assessment of prognostic factors in common ovarian tumors of varying malignancy].
    Demeter A, Várkonyi T, Csapó Z, Szánthó A, Oláh J, Papp Z.
    Magy Onkol; 2004 Jan; 48(3):259-65. PubMed ID: 15520877
    [Abstract] [Full Text] [Related]

  • 44. Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study.
    Jewell EL, Darcy KM, Hutson A, Lee PS, Havrilesky LJ, Grace LA, Berchuck A, Secord AA.
    Gynecol Oncol; 2009 Dec; 115(3):424-9. PubMed ID: 19767063
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. ErbB-3 predicts survival in ovarian cancer.
    Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Steiner E, Sehouli J, Edelmann J, Läuter J, Lessig R, Krishnamurthi K, Ullrich A, Hengstler JG.
    J Clin Oncol; 2006 Sep 10; 24(26):4317-23. PubMed ID: 16896008
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance.
    Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins AC, Li Y.
    Gynecol Oncol; 2007 Jun 10; 105(3):695-702. PubMed ID: 17368732
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. The clinicopathological significance of Bax and Bcl-2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma.
    Yigit S, Demir L, Tarhan MO, Cabuk FK, Ellidokuz H, Erten C, Somali I, Dirican A, Cakalagaoglu F.
    Neoplasma; 2012 Jun 10; 59(5):475-85. PubMed ID: 22668011
    [Abstract] [Full Text] [Related]

  • 53. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
    Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ.
    Clin Cancer Res; 2005 Sep 15; 11(18):6422-30. PubMed ID: 16166416
    [Abstract] [Full Text] [Related]

  • 54. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
    Gąsowska-Bodnar A, Bodnar L, Dąbek A, Cichowicz M, Jerzak M, Cierniak S, Kozłowski W, Baranowski W.
    Int J Gynecol Cancer; 2014 May 15; 24(4):687-96. PubMed ID: 24662134
    [Abstract] [Full Text] [Related]

  • 55. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways.
    Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, Cho KR.
    Cancer Cell; 2007 Apr 15; 11(4):321-33. PubMed ID: 17418409
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining.
    Kritpracha K, Hanprasertpong J, Chandeying V, Dechsukhum C, Geater A.
    J Obstet Gynaecol Res; 2005 Jun 15; 31(3):268-76. PubMed ID: 15916666
    [Abstract] [Full Text] [Related]

  • 58. Comparative immunohistochemical studies of bcl-2 and p53 proteins in benign and malignant ovarian endometriotic cysts.
    Nezhat F, Cohen C, Rahaman J, Gretz H, Cole P, Kalir T.
    Cancer; 2002 Jun 01; 94(11):2935-40. PubMed ID: 12115382
    [Abstract] [Full Text] [Related]

  • 59. [Prognostic differentiation of ovarian carcinomas by immunohistochemical analysis of estrogen receptor expression].
    Kieback DG, Press MF, McCamant SK, Atkinson EN, Möbus VJ, Runnebaum IB, Kreienberg R, Jones LA.
    Geburtshilfe Frauenheilkd; 1995 Apr 01; 55(4):189-94. PubMed ID: 7789706
    [Abstract] [Full Text] [Related]

  • 60. TTF-1 expression in primary ovarian epithelial neoplasia.
    Graham AD, Williams AR, Salter DM.
    Histopathology; 2006 May 01; 48(6):764-5. PubMed ID: 16681695
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.